Home › Cancer (all types) › NCT02280161

Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer

An Investigation of the Role of Germ-Line Mutations in Cancer Predisposition, Tumor Biology, and Response to Treatment

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Pathologically or clinical confirmed tissue diagnosis of a cancer
* Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

* Patients will be excluded if their cancer cannot be confirmed
* Refusal to sign the informed consent

About the study

This research trial studies germ-line mutations in blood and saliva samples from patients with cancer. Studying samples of blood and saliva from patients with cancer in the laboratory may help doctors learn more about how inherited genetic mutations can affect cancer predisposition (an inherited increase in the risk of developing cancer), their impact on treatment response, and their role in cancer development.

What is being tested

• cytology specimen collection procedure (other)

Sponsor: Jonsson Comprehensive Cancer Center · Participants: 2,000 · Started: Sep 16, 2014

Contact the study team

Official record on ClinicalTrials.gov — NCT02280161

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.